Physician profile
Patrick Mercho
NPI 1477164077
$1,332.19
in general payments reported to CMS, 2019-2025
18 companies · $886 in 2025
The $886 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $118 · 2024: $328 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,332.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $254.10 | 2024-2025 | Ingrezza |
| Emd Serono, INC. | $219.08 | 2024-2025 | |
| Abbvie INC. | $215.05 | 2024-2025 | |
| Lilly USA, LLC | $124.38 | 2025 | Kisunla |
| Jazz Pharmaceuticals INC. | $102.54 | 2023 | |
| Mdd US Operations, LLC | $90.20 | 2024-2025 | Apokyn |
| Tg Therapeutics, INC. | $53.54 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.09 | 2025 | Hyqvia |
| Astrazeneca Pharmaceuticals Lp | $32.93 | 2025 | Wainua |
| Lundbeck LLC | $32.86 | 2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $29.53 | 2025 | Austedo Xr |
| Merz Pharmaceuticals, LLC | $25.77 | 2025 | Xeomin, Ampyra, Inbrija |
| Acadia Pharmaceuticals INC | $24.04 | 2025 | Nuplazid |
| Pfizer INC. | $18.88 | 2025 | |
| Axsome Therapeutics, INC. | $16.99 | 2025 | Symbravo |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $16.99 | 2025 | |
| Alexion Pharmaceuticals, INC. | $15.39 | 2023 | Ultomiris |
| Janssen Biotech, INC. | $14.83 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mercho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.